Sartorius Stedim Biotech S.A
Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; reagents; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transp… Read more
Sartorius Stedim Biotech S.A (SDMHF) - Net Assets
Latest net assets as of December 2025: $4.12 Billion USD
Based on the latest financial reports, Sartorius Stedim Biotech S.A (SDMHF) has net assets worth $4.12 Billion USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($8.01 Billion) and total liabilities ($3.89 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $4.12 Billion |
| % of Total Assets | 51.46% |
| Annual Growth Rate | 18.09% |
| 5-Year Change | 137.97% |
| 10-Year Change | 440.18% |
| Growth Volatility | 25.33 |
Sartorius Stedim Biotech S.A - Net Assets Trend (2005–2025)
This chart illustrates how Sartorius Stedim Biotech S.A's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Sartorius Stedim Biotech S.A (2005–2025)
The table below shows the annual net assets of Sartorius Stedim Biotech S.A from 2005 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $4.12 Billion | +2.50% |
| 2024-12-31 | $4.02 Billion | +50.52% |
| 2023-12-31 | $2.67 Billion | +6.32% |
| 2022-12-31 | $2.51 Billion | +45.06% |
| 2021-12-31 | $1.73 Billion | +16.88% |
| 2020-12-31 | $1.48 Billion | +25.92% |
| 2019-12-31 | $1.18 Billion | +12.71% |
| 2018-12-31 | $1.04 Billion | +18.81% |
| 2017-12-31 | $879.45 Million | +15.18% |
| 2016-12-31 | $763.56 Million | +17.97% |
| 2015-12-31 | $647.22 Million | +20.19% |
| 2014-12-31 | $538.51 Million | +11.76% |
| 2013-12-31 | $481.84 Million | +10.84% |
| 2012-12-31 | $434.72 Million | +9.88% |
| 2011-12-31 | $395.63 Million | +8.37% |
| 2010-12-31 | $365.07 Million | -7.15% |
| 2009-12-31 | $393.20 Million | +5.80% |
| 2008-12-31 | $371.65 Million | +2.45% |
| 2007-12-31 | $362.76 Million | +114.74% |
| 2006-12-31 | $168.93 Million | +13.87% |
| 2005-12-31 | $148.35 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Sartorius Stedim Biotech S.A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 5996.9% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $2.70 Billion | 66.08% |
| Common Stock | $19.49 Million | 0.48% |
| Other Comprehensive Income | $1.37 Billion | 33.45% |
| Other Components | $1.00 | 0.00% |
| Total Equity | $4.09 Billion | 100.00% |
Sartorius Stedim Biotech S.A Competitors by Market Cap
The table below lists competitors of Sartorius Stedim Biotech S.A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
F.N.B. Corp
NYSE:FNB
|
$5.66 Billion |
|
PT Astra International Tbk
PINK:PTAIF
|
$5.67 Billion |
|
Guangdong Haid Group Co Ltd
SHE:002311
|
$5.67 Billion |
|
TERRENO REALTY DL -01
F:T37
|
$5.67 Billion |
|
MGIC Investment Corp
NYSE:MTG
|
$5.66 Billion |
|
China Oilfield Services Ltd Class A
SHG:601808
|
$5.65 Billion |
|
Churchill Downs Incorporated
NASDAQ:CHDN
|
$5.65 Billion |
|
Amkor Technology Inc
NASDAQ:AMKR
|
$5.65 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sartorius Stedim Biotech S.A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 3,986,600,000 to 4,088,967,948, a change of 102,367,948 (2.6%).
- Net income of 265,500,522 contributed positively to equity growth.
- Dividend payments of 67,074,867 reduced retained earnings.
- New share issuances of 200,000 increased equity.
- Other comprehensive income decreased equity by 103,512,407.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $265.50 Million | +6.49% |
| Dividends Paid | $67.07 Million | -1.64% |
| Share Issuances | $200.00K | +0.0% |
| Other Comprehensive Income | $-103.51 Million | -2.53% |
| Other Changes | $7.25 Million | +0.18% |
| Total Change | $- | 2.57% |
Book Value vs Market Value Analysis
This analysis compares Sartorius Stedim Biotech S.A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.86x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 140.68x to 4.86x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-12-31 | $1.45 | $204.04 | x |
| 2006-12-31 | $1.65 | $204.04 | x |
| 2007-12-31 | $3.54 | $204.04 | x |
| 2008-12-31 | $3.61 | $204.04 | x |
| 2009-12-31 | $3.84 | $204.04 | x |
| 2010-12-31 | $3.77 | $204.04 | x |
| 2011-12-31 | $4.27 | $204.04 | x |
| 2012-12-31 | $4.69 | $204.04 | x |
| 2013-12-31 | $5.19 | $204.04 | x |
| 2014-12-31 | $5.78 | $204.04 | x |
| 2015-12-31 | $6.96 | $204.04 | x |
| 2016-12-31 | $8.22 | $204.04 | x |
| 2017-12-31 | $9.46 | $204.04 | x |
| 2018-12-31 | $11.24 | $204.04 | x |
| 2019-12-31 | $12.57 | $204.04 | x |
| 2020-12-31 | $15.84 | $204.04 | x |
| 2021-12-31 | $17.96 | $204.04 | x |
| 2022-12-31 | $26.58 | $204.04 | x |
| 2023-12-31 | $28.62 | $204.04 | x |
| 2024-12-31 | $41.19 | $204.04 | x |
| 2025-12-31 | $42.02 | $204.04 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Sartorius Stedim Biotech S.A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 6.49%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 8.95%
- • Asset Turnover: 0.37x
- • Equity Multiplier: 1.96x
- Recent ROE (6.49%) is below the historical average (14.78%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | 14.91% | 4.57% | 1.34x | 2.44x | $7.28 Million |
| 2006 | 17.18% | 5.57% | 1.38x | 2.23x | $12.13 Million |
| 2007 | 1.31% | 1.76% | 0.42x | 1.77x | $-31.53 Million |
| 2008 | 3.54% | 3.56% | 0.56x | 1.76x | $-23.89 Million |
| 2009 | 7.40% | 7.25% | 0.60x | 1.70x | $-10.23 Million |
| 2010 | 10.55% | 8.90% | 0.66x | 1.80x | $2.00 Million |
| 2011 | 10.93% | 9.02% | 0.66x | 1.83x | $3.66 Million |
| 2012 | 13.14% | 10.43% | 0.69x | 1.84x | $13.56 Million |
| 2013 | 13.86% | 11.26% | 0.68x | 1.82x | $18.44 Million |
| 2014 | 13.60% | 10.60% | 0.75x | 1.70x | $19.19 Million |
| 2015 | 18.40% | 13.34% | 0.83x | 1.66x | $53.85 Million |
| 2016 | 20.27% | 14.61% | 0.88x | 1.58x | $77.88 Million |
| 2017 | 18.47% | 14.90% | 0.77x | 1.61x | $73.89 Million |
| 2018 | 20.07% | 17.16% | 0.77x | 1.52x | $104.41 Million |
| 2019 | 20.24% | 16.28% | 0.79x | 1.57x | $118.62 Million |
| 2020 | 23.01% | 17.59% | 0.62x | 2.10x | $189.93 Million |
| 2021 | 25.03% | 14.35% | 0.73x | 2.39x | $248.81 Million |
| 2022 | 35.77% | 25.08% | 0.69x | 2.07x | $631.17 Million |
| 2023 | 11.74% | 11.16% | 0.36x | 2.93x | $45.91 Million |
| 2024 | 4.39% | 6.30% | 0.34x | 2.07x | $-223.56 Million |
| 2025 | 6.49% | 8.95% | 0.37x | 1.96x | $-143.40 Million |
Industry Comparison
This section compares Sartorius Stedim Biotech S.A's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $2,683,526,542
- Average return on equity (ROE) among peers: -32.48%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Sartorius Stedim Biotech S.A (SDMHF) | $4.12 Billion | 14.91% | 0.94x | $5.66 Billion |
| ANGELALIGN TECHNOLOGY INC (AGLFF) | $480.24 Million | 2.52% | 0.41x | $405.57 Million |
| Akoya Biosciences Inc (AKYA) | $-30.16 Million | 0.00% | 0.00x | $16.24 Million |
| Alcon AG (ALC) | $19.68 Billion | 1.70% | 0.48x | $37.82 Billion |
| Align Technology Inc (ALGN) | $3.85 Billion | 10.94% | 0.61x | $11.75 Billion |
| AngioDynamics Inc (ANGO) | $355.71 Million | 3.06% | 0.15x | $354.40 Million |
| Ansell Limited (ANSLF) | $386.33 Million | -0.45% | 0.87x | $2.58 Billion |
| AptarGroup Inc (ATR) | $2.07 Billion | 11.57% | 1.03x | $8.27 Billion |
| AtriCure Inc (ATRC) | $72.60 Million | -15.79% | 0.54x | $1.42 Billion |
| Avinger Inc (AVGR) | $-35.69 Million | 0.00% | 0.00x | $1.26 Million |
| Anteris Technologies Global Corp. Common Stock (AVR) | $9.03 Million | -338.35% | 0.77x | $156.14 Million |